Two immunotherapy drugs for advanced cervical cancer
Treatments studied
Part of Cancer, Women’s health & pregnancy clinical trials.
This study tests whether combining two immune-boosting drugs (MRG003 and QL1706) can help treat cervical cancer that has come back or spread after prior chemotherapy. The goal is to see if this combination works better than standard options and is safe to use.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Your cervical cancer must have returned or spread after at least one round of platinum-based chemotherapy
- You must be 18 years or older with at least 12 weeks of expected lifespan
- Your cancer must be measurable on imaging scans
- You must be in good enough health to handle treatment (ECOG score 0–1, meaning you can do most daily activities)
- You cannot have active cancer elsewhere in your body or untreated brain metastases (cancer spread to the brain)
- Your organs (liver, kidneys, heart) must function well enough to safely receive the study drugs
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new combination of two immunotherapy drugs plus chemotherapy (with or without an anti-VEGF drug) followed by standard chemoradiation for women with advanced cervical cancer that hasn't spread beyond the pelvis. It aims to see if this approach can shrink tumors more effectively than standard treatment alone.
This trial tests a combination of three types of cancer-fighting drugs—an immunotherapy (camrelizumab), a targeted therapy (famitinib), and chemotherapy—to treat cervical cancer that has returned or spread. The goal is to see if this combination works better than standard treatment.
This trial tests whether adding a new immunotherapy drug (QL1706) to chemotherapy before radiation treatment can help patients with advanced cervical cancer that hasn't spread to distant organs. The goal is to improve outcomes and survival.
This trial tests whether adding a new immunotherapy drug called QL1706 to standard chemotherapy before surgery can help treat early-stage cervical cancer better. The goal is to shrink tumors and improve outcomes for patients who haven't had immune therapy before.
This trial is testing whether adding the immunotherapy drug QL1706 to standard chemotherapy before surgery can improve outcomes for women with a certain type and stage of cervical cancer. It is for women whose cancer has not been treated yet and who are healthy enough for the treatment.
This trial tests a new treatment (QL706) combined with chemotherapy, with or without bevacizumab, for cervical cancer that has stopped responding to previous immunotherapy. It aims to find a better option for patients whose disease has progressed after anti-PD-1/PD-L1 therapy.
Hear when a new Recurrent or Metastatic Cervical Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.